Equities

Brainsway Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Brainsway Ltd

Actions
Health CareMedical Equipment and Services
  • Price (USD)23.18
  • Today's Change11.34 / 95.69%
  • Shares traded57.25k
  • 1 Year change+396.63%
  • Beta1.2047
Data delayed at least 15 minutes, as of Mar 03 2026 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.

  • Revenue in USD (TTM)98.19m
  • Net income in USD12.50m
  • Incorporated2006
  • Employees120.00
  • Location
    Brainsway Ltd16 Hartum Street Rad Tower14Th Floor, Har HaHotzvimJERUSALEM 9777516IsraelISR
  • Phone+972 25813140
  • Fax+972 25812517
  • Websitehttps://www.brainsway.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Carlsmed Inc-100.00bn-100.00bn353.13m100.00--3.29----------4.01------------------------11.91--0.1265--97.16---31.49------
Evolent Health Inc1.88bn-579.40m391.85m4.20k--0.9437--0.2089-5.15-5.1516.433.720.8445--5.18446,721.20-24.06-7.51-31.98-10.2021.3120.74-28.49-8.76---0.10360.7004---26.5615.20-519.99--1.42--
Standard Biotools Inc105.90m-61.49m399.95m818.00--0.9426--3.78-0.162-0.19730.27751.100.17951.804.52---10.42-23.14-12.23-27.9148.3847.79-58.06-92.674.01--0.0007---6.24-9.1957.05---8.17--
Cerus Corp225.97m-15.96m409.33m281.00--6.66--1.81-0.0848-0.08481.200.32011.121.998.35804,163.70-7.91-20.38-12.30-31.9660.5061.15-7.09-25.371.29-1.040.5772--7.7816.5144.20---20.50--
Brainsway Ltd - ADR98.19m12.50m452.09m120.0077.4312.5731.424.600.29940.29942.261.840.53033.0411.35818,233.306.75-8.729.39-11.2774.9275.2612.73-17.453.11--0.046--29.0412.17169.60--2.76--
AngioDynamics, Inc.307.31m-27.71m455.04m675.00--2.60--1.48-0.6731-0.67317.474.241.102.127.02455,268.20-9.87-13.69-13.83-16.1954.5852.46-9.02-21.321.33--0.0329---3.762.0681.56---10.06--
Neuropace Inc94.86m-23.99m457.52m209.00--24.86--4.82-0.7535-0.75352.980.55640.93211.467.16515,565.20-23.57-35.71-28.36-44.3476.7773.39-25.28-60.453.94-3.580.7603--22.1416.6717.64---8.15--
Pacific Biosciences of California Inc160.01m-546.38m459.04m485.00--85.81--2.87-1.83-1.830.53340.01770.15651.965.08329,907.20-53.45-22.47-57.35-24.2933.9733.11-341.47-214.454.47-21.700.9918--3.8915.19-76.34--49.33--
Orthopediatrics Corp227.41m-45.61m468.50m562.00--1.34--2.06-1.96-1.969.7413.930.46280.51494.83404,644.10-9.28-5.87-9.97-6.4471.7374.27-20.06-16.553.52-5.960.2214--37.6523.06-80.33--4.29--
Myriad Genetics Inc824.50m-365.90m494.66m2.70k--1.34--0.600-3.95-3.958.903.940.95098.536.97305,370.40-42.20-15.51-50.95-18.0269.9369.98-44.38-23.602.26-7.790.2458---1.56---187.43------
Mesa Laboratories Inc247.54m3.73m504.75m730.00141.192.7017.562.040.64710.647144.8133.790.56783.406.28339,097.300.8564-8.811.13-9.7162.4061.981.51-25.151.451.620.4709--11.4715.4199.22--24.600.00
Beta Bionics Inc100.25m-73.20m513.50m420.00--1.78--5.12-1.95-1.952.486.480.41912.556.34238,692.90-30.60---34.34--55.40---73.02--7.96--0.00--53.94---33.68------
Orthofix Medical Inc822.31m-92.19m523.08m1.61k--1.15--0.6361-2.34-2.3420.7611.300.9431.426.08512,343.90-10.57-12.43-13.13-15.3868.8369.37-11.21-12.991.43-1.660.2803--2.8515.1326.83--7.31--
Varex Imaging Corp854.40m-67.70m539.67m2.40k--1.13--0.6316-1.63-1.6319.3411.380.70321.856.00356,000.00-5.55-0.3327-6.45-0.395534.1533.16-7.89-0.46611.872.220.4321--4.142.73-47.38---0.5159--
Cytek Biosciences Inc201.49m-66.54m570.76m702.00--1.67--2.83-0.5197-0.51971.582.660.41932.103.27287,027.10-13.85-3.42-16.32-3.8551.8456.95-33.02-8.934.42--0.0196--0.518816.76-1,005.30--22.05--
Data as of Mar 03 2026. Currency figures normalised to Brainsway Ltd's reporting currency: US Dollar USD

Institutional shareholders

13.56%Per cent of shares held by top holders
HolderShares% Held
Masters Capital Management LLCas of 31 Dec 20251.00m5.11%
Acadian Asset Management LLCas of 31 Dec 2025409.74k2.09%
Essex Investment Management Co. LLCas of 31 Dec 2025304.18k1.55%
Renaissance Technologies LLCas of 31 Dec 2025276.86k1.41%
Cresset Asset Management LLCas of 31 Dec 2025157.46k0.80%
ARK Investment Management LLCas of 31 Dec 2025127.33k0.65%
More Mutual Funds Management (2013) Ltd.as of 31 Dec 2025114.96k0.59%
Legato Capital Management LLCas of 31 Dec 202597.38k0.50%
Huntleigh Advisors, Inc.as of 31 Dec 202587.08k0.45%
Eagle Global Advisors LLCas of 31 Dec 202581.30k0.42%
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.